Octreotide Impurity 13 is an octreotide-related peptide characterized as a specific process or degradation product. Small differences in sequence or protecting-group history change its cyclization, ring conformation, and retention behavior. Researchers use it to establish impurity thresholds and validate analytical separation. Applications include QC profiling, process-development analysis, and structural-variant comparison.
CAT No: R2764
CAS No:1546983-33-8
Synonyms/Alias:(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-N-acetyl-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
Octreotide Impurity 13 is a synthetic peptide derivative structurally related to octreotide, a well-characterized somatostatin analog. As a defined impurity, it represents a specific byproduct or structural variant generated during the chemical synthesis or degradation of octreotide. Its presence and characterization are of critical importance in peptide manufacturing, quality control, and analytical method development. The unique sequence and physicochemical properties of this impurity allow it to serve as a valuable reference standard in various research and industrial settings, supporting the rigorous assessment of peptide drug purity and stability.
Analytical method development: In the context of pharmaceutical analysis, Octreotide Impurity 13 is widely utilized as a reference compound for the validation and optimization of chromatographic techniques such as HPLC and LC-MS. Its inclusion in analytical protocols enables the precise identification and quantification of impurities within octreotide bulk substances or formulated products. By providing a known retention time and spectral profile, it supports the establishment of robust impurity profiling methods, ensuring that analytical procedures are sensitive and selective enough to detect even minor structural variants.
Quality control in peptide manufacturing: The use of this impurity as a system suitability standard is essential for ongoing quality assurance in peptide production. By spiking manufacturing samples with defined amounts of Octreotide Impurity 13, laboratories can verify the performance of their analytical systems and monitor batch-to-batch consistency. This practice helps manufacturers detect process-related deviations, assess the effectiveness of purification steps, and maintain compliance with stringent quality requirements for peptide therapeutics, even though the impurity itself is not intended for clinical use.
Degradation pathway elucidation: The study of Octreotide Impurity 13 provides critical insights into the chemical stability and degradation pathways of octreotide under various storage or processing conditions. By tracking the formation and accumulation of this impurity over time, researchers can identify the underlying mechanisms of peptide degradation, such as oxidation, deamidation, or sequence truncation. These findings inform the design of improved synthetic routes, formulation strategies, and storage protocols to minimize impurity formation and enhance product shelf life.
Peptide synthesis process optimization: In research and industrial peptide synthesis, monitoring the generation of specific byproducts like Octreotide Impurity 13 enables chemists to refine synthetic methodologies. Detailed analysis of impurity profiles can reveal inefficiencies or side reactions in solid-phase or solution-phase peptide assembly. By understanding the conditions that favor or suppress the formation of such impurities, process chemists can adjust reaction parameters, purification steps, or reagent choices to achieve higher yields of target peptides and reduce unwanted byproducts.
Reference material for regulatory documentation: Although not intended for clinical or therapeutic applications, Octreotide Impurity 13 plays a crucial role in supporting regulatory submissions for peptide-based pharmaceuticals. Its well-characterized structure and analytical behavior make it an indispensable reference for compiling impurity profiles, risk assessments, and validation reports required by regulatory agencies. The availability of this impurity as a standard ensures that manufacturers can provide comprehensive documentation demonstrating the identity, quantity, and control of process-related impurities in their products.
2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
3. Emu oil in combination with other active ingredients for treating skin imperfections
5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More